TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07845071: An Open-Label, Safety and Efficacy Study of Cebranopadol in Participants With Acute Pain With Surgical or Non-Surgical Origin

Sponsor: Adneuris Therapeutics, Inc. · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 160 pts

Competing Trials Overlap

10 Active Trials

Excess Burn Exposure

$2,592,920

Rescue Site Savings

+$1,697,184

Unlock Full NCT07845071 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07845071 Rescue Dossier →